
Epilepsy
Improving diagnosis and treatments for refractory epilepsy.
Personalised treatments to improve seizure control.
Around 2% of people will develop epilepsy during their lifetime. Currently there are around 100,000 children and adults in Queensland with epilepsy. More than a third of patients don’t respond to current anti-epilepsy drugs.
This project will incorporate genomic testing into the model of care for patients with neurological disorders like refractory epilepsy.
This approach can provide patients and their families with a cause for the disorder, as well as an opportunity for better treatment choices suited to the patient.
The ultimate goal of this work is to improve the quality of care for patients and their families, and improve efficiencies in healthcare.
This is a clinical implementation project, which applies best evidence to clinical practice and is intended to become standard of care following project completion.
Project Investigators
Project leaders engage with and draw upon the expertise of partners within universities, research institutes and hospital and health services around Queensland.
Associate Professor Lata Vadlamudi, Metro North Hospital & Health Services and The University of Queensland (lead)
Professor David Reutens, Metro North Hospital & Health Services and The University of Queensland
Dr Cecilie Lander, Metro North Hospital & Health Services
Dr Alice-Ann Sullivan, Metro North Hospital & Health Services
Dr James Pelekanos, Metro North Hospital & Health Services
Dr Xiaochua Chen, Metro North Hospital & Health Services
Dr Kate Sinclair, Queensland Children’s Hospital
Dr Stephen Malone, Queensland Children’s Hospital
Dr Kate Riney, Queensland Children’s Hospital
Dr Sophie Calvert, Queensland Children’s Hospital
Dr Geoff Wallace, Queensland Children’s Hospital
Dr Adriane Sinclair, Queensland Children’s Hospital
Dr Ubaid Shah, Queensland Children’s Hospital
Dr Deepa Srinivasan, Queensland Children’s Hospital
Dr Ian Wilson, Cairns and Hinterland Hospital and Health Services